Technology ID

DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders

Lead Inventor
Morasso, Maria (NIAMS)
Research Materials
Therapeutic Areas
Development Stages
Pre-clinical (in vivo)
Research Products
Animal Models
Lead IC

This technology includes the creation of DLX3-floxed mice, specifically designed for conditional deletion of the DLX3 gene via Cre-mediated recombination. This innovative approach aims to develop mouse models for studying ectodermal dysplasia disorders. Ectodermal dysplasias are a diverse group of genetic conditions affecting the development of ectodermal structures, including hair, teeth, and bones. The DLX3f/f mice are particularly valuable for modeling specific disorders such as Tricho-dento-osseous syndrome (TDO), Amelogenesis Imperfecta (AI), and Dentinogenesis Imperfecta (DI). By selectively ablating the DLX3 gene, the genetic and phenotypic aspects of these disorders can be closely mimicked, enhancing our understanding and potentially leading to new therapeutic strategies.

Commercial Applications
A potential use of DLX3f/f mice is for the generation of mouse models for ectodermal dysplasia disorders, perform targeted drug development, and to study molecular mechanisms of DLX3 regulation in skin and ectodermal appendages.

Competitive Advantages
Floxed DLX3 allele allows conditional knockout of this gene in different tissues at specific time during development.
Licensing Contact:
Knezevic, Vladimir